As part of their long-term cooperation, DSM and US industrial bioscience company Amyris have entered into another agreement to develop and produce a new class of human nutrition ingredients. This latest deal follows several agreements between the two companies that are focused on developing and producing new products within the animal and human health and nutrition sectors.

John Melo, president and CEO of Amyris, said: “Our partnership with DSM will allow us to introduce a new generation of ingredients targeted for human nutrition. This collaboration includes a material initial payment and will result in significant medium-term product revenue.”

DSM will fund the technology’s development and will also commercialize any new human nutrition products that use the ingredients, currently targeted for market launch in 2019.

The Dutch group agreed in May to initially invest $25 million into Amyris, gaining an equity stake of about 12%, with the possibility of investing another $25 million, subject to certain conditions.

In separate news, DSM is to acquire Twilmij, a Dutch producer of animal feed supplements, for an undisclosed sum. The deal also includes Twilmij’s associated company Kwalipak, which offers specialty small-pack solutions for specific feed applications.

The transaction is expected to close by the end of 2017.